Fig. 1 | Leukemia

Fig. 1

From: HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation

Fig. 1

Allo-CART19 cell expansion, B-cell aplasia and lymphocyte phenotypic analysis occurred in the peripheral blood of patients. a The flow cytometry results showed that the proportion of MCART19 cells increased significantly in the peripheral blood of patients 1, 2, and 4. Compared with the other five patients, these three patients all had a good response to MCART19 cell therapy. b B-cell dysplasia occurred in patients 1, 2, and 4, who received MCART19 cell therapy. There was only a transient reduction in the proportion of peripheral blood B cells in the four patients treated with HCART19 cell therapy. c NK, NKT, B, TH, and CTL cells evaluated before and after cell infusion by flow cytometry. The number of NK cells in the five patient datasets available for review increased after infusion. d T cell phenotypic analysis before and after allo-CART19 cell infusion. Data for five patients were available and are displayed. Tn naive T cell, Te effector T cell, Tcm central memory T cell, Tem effector memory T cell. e Expression of PD-1 on T cells measured by flow cytometry before and after allogeneic CAR-T-cell infusion. All patients completed this evaluation, and almost all patients had increased PD-1 expression after infusion. f Treg cells measured by flow cytometry before and after allogeneic CAR-T-cell infusion. The proportion of Treg cells in patient 3 increased significantly after treatment

Back to article page